2. Academic Validation
  3. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

  • J Med Chem. 1992 Nov 13;35(23):4450-4. doi: 10.1021/jm00101a023.
E C Taylor 1,  D Kuhnt,  C Shih,  S M Rinzel,  G B Grindey,  J Barredo,  M Jannatipour,  R G Moran
Affiliations

Affiliation

  • 1 Department of Chemistry, Princeton University, New Jersey 08544.
PMID: 1447744 DOI: 10.1021/jm00101a023
Abstract

N-[4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid (15), prepared in five steps from 2-pivaloyl-7-deazaguanine, has been found to be an antitumor agent with its primary site of action at Thymidylate Synthase rather than purine synthesis. This compound appears to be a promising candidate for clinical evaluation.

Figures